Bioceres Crop Solutions 과거 순이익 실적
과거 기준 점검 0/6
Bioceres Crop Solutions 의 수입은 연평균 -53.6%의 비율로 감소해 온 반면, Chemicals 산업은 연평균 3.8%의 비율로 감소했습니다. 매출은 연평균 5.8%의 비율로 증가해 왔습니다.
핵심 정보
-53.58%
순이익 성장률
-47.75%
주당순이익(EPS) 성장률
| Chemicals 산업 성장률 | 12.93% |
| 매출 성장률 | 5.84% |
| 자기자본이익률 | -74.24% |
| 순이익률 | -26.08% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
분석 기사 • Feb 10
Investors Don't See Light At End Of Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Tunnel And Push Stock Down 54%
To the annoyance of some shareholders, Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) shares are down a considerable 54...
내러티브 업데이트 • Dec 17
BIOX: Portfolio Recapitalization Progress Will Eventually Overcome Argentina Liquidity Headwinds
Analysts have trimmed their price target on Bioceres Crop Solutions by roughly $0.10 per share, citing heightened Argentina-related liquidity volatility and increased uncertainty around the company’s portfolio recapitalization efforts. Analyst Commentary Analysts acknowledge that Bioceres retains a differentiated portfolio and strategic exposure to key agricultural markets, but sentiment has turned more cautious as near term risks have become more prominent in their valuation work.내러티브 업데이트 • Dec 03
BIOX: Next Generation Product Pipeline Will Offset Argentina Liquidity Pressures
Analysts have trimmed their price target on Bioceres Crop Solutions to around $2.25 from approximately $3.63, reflecting concerns over Argentina related liquidity pressures and portfolio recapitalization challenges, even as they continue to see long term value in the company’s next generation product pipeline. Analyst Commentary Street research on Bioceres Crop Solutions reflects a mixed backdrop, with liquidity concerns and execution risks in Argentina offset by continued confidence in the long term earnings power of its next generation product portfolio.내러티브 업데이트 • Nov 19
BIOX: Portfolio Recapitalization Will Overcome Argentina Liquidity Pressure Ahead
The analyst price target for Bioceres Crop Solutions was revised downward from $3.75 to $3.63. Analysts cited increased pressure from liquidity concerns and recent portfolio challenges as key factors for the adjustment.분석 기사 • Nov 17
Is Bioceres Crop Solutions (NASDAQ:BIOX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...내러티브 업데이트 • Nov 02
BIOX: Recovery From Argentina Volatility Will Drive Future Upside Potential
Analysts have lowered their fair value price target for Bioceres Crop Solutions from $4.17 to $3.75 per share. They cite concerns about Argentina's economic volatility, recent earnings shortfalls, and increased hurdles to the company's portfolio strategy.분석 기사 • Oct 30
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) shareholders are no doubt pleased to see that the share price has bounced...내러티브 업데이트 • Oct 18
Transition To Capital-Light Model And Global Expansion Will Shape Future Success
Analysts have revised their price target for Bioceres Crop Solutions downward from $8 to $5, citing weaker-than-expected Q4 results and leadership transitions. However, they continue to highlight potential in the company’s pipeline for future value creation.내러티브 업데이트 • Oct 04
Transition To Capital-Light Model And Global Expansion Will Shape Future Success
Analysts have lowered their price target for Bioceres Crop Solutions from $8 to $5, citing weaker-than-expected Q4 results and concerns over executive turnover. However, they continue to see long-term value in the company's innovation pipeline.분석 기사 • Sep 15
The Market Doesn't Like What It Sees From Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Revenues Yet As Shares Tumble 31%
Unfortunately for some shareholders, the Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) share price has dived 31% in the...Seeking Alpha • Sep 09
Bioceres Crop Solutions: Waiting For Gross Profit To Turn (Downgrade)
Summary Downgrade Bioceres Crop Solutions Corp. to Hold due to Argentina's volatile currency, credit constraints, and a challenging shift in the seed sales model. Recent results show sharply lower revenues, deeper losses, but disciplined cash management, and a focus on cost reductions going forward. Valuation sits at 3.5x gross profit and 8.5–11x EV/EBITDA, but earnings risk and potential dilution remain high. If cost cuts and inventory normalization drive EBITDA recovery, I may reconsider BIOX stock, but for now, patience is warranted. Read the full article on Seeking Alpha분석 기사 • Aug 01
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Not Doing Enough For Some Investors As Its Shares Slump 25%
The Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) share price has fared very poorly over the last month, falling by a...분석 기사 • Jul 22
Bioceres Crop Solutions (NASDAQ:BIOX) Use Of Debt Could Be Considered Risky
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Apr 04
Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Mar 07
Bioceres Crop Solutions' (NASDAQ:BIOX) Weak Earnings May Only Reveal A Part Of The Whole Picture
Last week's earnings announcement from Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) was disappointing to investors...분석 기사 • Mar 05
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Might Not Be As Mispriced As It Looks After Plunging 41%
The Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Feb 13
Bioceres Is Approaching Distressed Prices, But I Remain On The Sidelines
Summary Bioceres Crop Solutions Corp. reported a disappointing Q2 2025 with revenues down 24%, driven by Argentina's economic crisis, despite improved international sales. BIOX stock is down 62% year-over-year, and I maintain a Hold rating due to concerns about the company's ability to turn around. The shift to a licensing model for HB4 technology and R&D cuts may improve short-term finances but pose long-term risks. Despite a lower valuation, Bioceres' financial risks and management's past decisions make it unattractive until more data on turnaround effectiveness is available. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Bioceres Is Getting Cheaper, Not Yet An Opportunity But More Interesting
Summary Bioceres' 1Q25 results were challenging due to adverse weather in Argentina, affecting crop nutrition, protection, and seeds, but potential recovery is expected in 2Q25. BIOX has depreciated significantly, now trading at $6.7 per share, with a market cap of $400 million, making it a more interesting Hold. Despite some improvements, HB4 commercialization remains underwhelming, and financial risks persist, warranting caution before investing in potential developments. Valuation is approaching reasonable levels, but the company's execution, financial risk, and lack of clear reporting keep me on the sidelines for now. Read the full article on Seeking Alpha분석 기사 • Sep 28
Take Care Before Jumping Onto Bioceres Crop Solutions Corp. (NASDAQ:BIOX) Even Though It's 29% Cheaper
Bioceres Crop Solutions Corp. ( NASDAQ:BIOX ) shareholders that were waiting for something to happen have been dealt a...
새로운 내러티브 • Sep 18
HB4 Wheat's US Approval Sparks Global Expansion And Profit Growth Surge
Approval of HB4 Wheat in the US highlights significant expansion and revenue opportunities, enhancing global acceptance and credibility of HB4 technology.Seeking Alpha • Sep 17
Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices
Summary Bioceres' 4Q24 results disappointed, with flat profitability and a 15% stock drop, driven by a bear market in agricultural commodities and commercialization challenges for HB4 products. The company's debt rose, particularly short term, with unclear maturity risks, and profitability challenges persisted despite top-line growth. Bioceres is shifting tactics for HB4, reducing the priority of its identity-protected program to manage working capital and focusing more on its bio solutions segment. Given low earnings yields, high debt, and market volatility, I rate Bioceres as a Hold, doubting its ability to achieve necessary growth for fair valuation. Read the full article on Seeking Alpha분석 기사 • Aug 03
These 4 Measures Indicate That Bioceres Crop Solutions (NASDAQ:BIOX) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Seeking Alpha • Mar 23
Bioceres Needs To Add Clarity Around Borrowings
Summary Bioceres is an agricultural supply company with growth potential in seed genetics and biopesticides markets. The company's 2Q24 results showed revenue growth and stable cost structure, leading to profitability. These were expected, given the Argentinian drought in 2023. Concerns remain about the company's high debt maturities and lack of clarity on its debt and refinancing plans. The company's valuation is that of a high growth company, and yet Bioceres is not showing a growth trend. Read the full article on Seeking Alpha분석 기사 • Feb 03
Bioceres Crop Solutions (NASDAQ:BIOX) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Oct 04
Does Bioceres Crop Solutions (NASDAQ:BIOX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Jun 21
Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Popularity With Investors Is Clear
Bioceres Crop Solutions Corp.'s ( NASDAQ:BIOX ) price-to-sales (or "P/S") ratio of 2x may not look like an appealing...분석 기사 • May 09
Here's Why Bioceres Crop Solutions (NASDAQ:BIOX) Is Weighed Down By Its Debt Load
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Sep 06
Bioceres: A Resilient Small Cap With Conference Appearances After Thursday's Earnings
Summary Corporate conference season is underway, and one Chemicals company is expected to speak at three events through mid-November. Bioceres Crop Solutions also has an earnings release due out Thursday morning, which should move shares in the near term. The stock has been a strong outperformer this year but has a mixed earnings history. I look to clues from the options market on where the stock might go. It is conference season on Wall Street. Investors must pay close attention to corporate events that might impact the stocks they own. One Materials sector company, a small cap, features three potentially market-moving conferences/forums at which the firm's management team is expected to speak. Often at these gatherings, fresh industry news and trends are presented along with key updates on individual companies. The Materials sector is particularly interesting right now given a slew of macro headwinds impacting both domestic and foreign firms. Weather-related trends are also constantly in the news this summer. One Argentina-based Chemicals stock has been resilient in the face of so much uncertainty from interest rates to currencies to climate change. According to CFRA Research, Bioceres Crop Solutions Corp. (BIOX), together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The $846 million market cap Argentina-based Chemicals company in the Materials sector has slightly negative GAAP earnings over the past 12 months and does not pay a dividend, according to The Wall Street Journal. On valuation, earnings are seen as rising this year and next, according to CFRA's forecast. Assuming $0.55 of EPS next year, the stock trades at a high 25-times forward earnings multiple. On a price-to-sales ratio basis, the value is not as high: just 2.3x. For context, according to Koyfin Charts, Bioceres' price-to-sales ratio peaked near 3.0x in mid-2021 with a low of 0.8x in late 2019. Bioceres: Earnings Outlook CFRA BIOX: Historical Price-To-Sales Ratio Trend Koyfin Charts Looking ahead, Wall Street Horizon's data show three events that could influence BIOX shares over the coming two-plus months. Credit Suisse 35th Annual Specialties & Basics Conference 2022: Sept 13-14 Lake Street Capital Markets 6th Annual Best Ideas Growth Conference 2022: Sept 14 S&P Global Crop Science Forum 2022: Nov. 10 There's also a critical Q4 2022 earnings date before the open on Thursday of this week, with an earnings call immediately after results are released. Investors can listen live here. Corporate Event Calendar: Earnings & Conferences Provide Volatility Catalysts Wall Street Horizon The Options AngleSeeking Alpha • Aug 23
Bioceres Crop Solutions jumps 15% after investor pitch
Bioceres Crop Solutions (NASDAQ:BIOX) soared 15% in after hours trading after an investor was bullish on the agriculture company. Bioceres (BIOX) "is a company that I think is going to be the future green Monsanto," Ospraie Management founder and managing partner Dwight Anderson said in an interview with CNBC. "There revenues are exploding. They are exactly in the right position in terms of their customer base and distribution and environmentally friendly products." He expects Bioceres (BIOX) shares may be 2x or 3x higher in the next two years. Ospraie Management is the third largest holder of Bioceres with a 10% stake. Bioceres (BIOX) is scheduled to report fiscal Q4 results on Sept. 8.분석 기사 • Apr 10
We Think Bioceres Crop Solutions (NASDAQ:BIOX) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Seeking Alpha • Mar 31
Bioceres Has Not Resolved Its Major Risks And Is Growing Based On Commodities Bullishness
Bioceres has a profitable segment based on its subsidiary Rizobacter, that sells adjuvants, micro beaded fertilizers and other agricultural solutions. Rizobacter's profits are growing significantly aided by the bull market in agricultural commodities. Bioceres uses Rizobacter's profits and debt to fund its growth strategy based on HB4 technology and further acquisitions. The problem is that HB4's market is difficult to estimate. To increase risk, a high level of debt puts Bioceres in a difficult situation if commodities prices recede. Bioceres continues in the same vein with the proposal to merge with Marrone Bio Innovations.매출 및 비용 세부 내역
매출 및 비용 세부 내역
Bioceres Crop Solutions가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 255 | -67 | 83 | 9 |
| 31 Dec 25 | 277 | -59 | 89 | 12 |
| 30 Sep 25 | 318 | -56 | 103 | 16 |
| 30 Jun 25 | 333 | -55 | 108 | 15 |
| 31 Mar 25 | 383 | -9 | 103 | 17 |
| 31 Dec 24 | 408 | 2 | 103 | 17 |
| 30 Sep 24 | 441 | 2 | 102 | 17 |
| 30 Jun 24 | 465 | 4 | 107 | 17 |
| 31 Mar 24 | 446 | 3 | 106 | 16 |
| 31 Dec 23 | 455 | 22 | 104 | 16 |
| 30 Sep 23 | 409 | 14 | 102 | 16 |
| 30 Jun 23 | 419 | 19 | 99 | 15 |
| 31 Mar 23 | 416 | 15 | 95 | 13 |
| 31 Dec 22 | 391 | -19 | 88 | 11 |
| 30 Sep 22 | 389 | -8 | 78 | 9 |
| 30 Jun 22 | 328 | -7 | 65 | 7 |
| 31 Mar 22 | 308 | -2 | 58 | 7 |
| 31 Dec 21 | 275 | 4 | 52 | 6 |
| 30 Sep 21 | 231 | 1 | 46 | 6 |
| 30 Jun 21 | 207 | -7 | 45 | 6 |
| 31 Mar 21 | 174 | -5 | 37 | 4 |
| 31 Dec 20 | 164 | -7 | 35 | 4 |
| 30 Sep 20 | 178 | 3 | 34 | 4 |
| 30 Jun 20 | 172 | 3 | 33 | 4 |
| 31 Mar 20 | 174 | 0 | 36 | 5 |
| 31 Dec 19 | 167 | -18 | 36 | 5 |
| 30 Sep 19 | 167 | -23 | 36 | 4 |
| 30 Jun 19 | 160 | -18 | 34 | 4 |
| 31 Mar 19 | 142 | -26 | 29 | 3 |
| 31 Dec 18 | 145 | -8 | 28 | 3 |
| 30 Sep 18 | 129 | -13 | 29 | 4 |
| 30 Jun 18 | 133 | -11 | 31 | 4 |
| 30 Jun 17 | 94 | -12 | 27 | 4 |
| 31 Dec 16 | 41 | -6 | 8 | 1 |
| 31 Dec 15 | 5 | -1 | 1 | 0 |
양질의 수익: BIOX 은(는) 현재 수익성이 없습니다.
이익 마진 증가: BIOX는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: BIOX은 수익성이 없으며 지난 5년 동안 손실이 연평균 53.6% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 BIOX의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: BIOX은 수익성이 없어 지난 해 수익 성장률을 Chemicals 업계(0.1%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: BIOX는 현재 수익성이 없으므로 자본 수익률이 음수(-74.24%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/13 04:47 |
| 종가 | 2026/05/13 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/06/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Bioceres Crop Solutions Corp.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Austin Moeller | Canaccord Genuity |